FSI “State Institute of Drugs and Good Practices” (FSI “SID & GP”) of the Ministry of Industry and Trade of Russia and the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia entered into a memorandum of understanding. The document, aimed at developing cooperation between the two countries in the field of GMP inspection, was signed during the XXIX St. Petersburg International Economic Forum (SPIEF-2026).
The memorandum envisages establishing bilateral exchange of information and best practices on the regulation and monitoring of various types of medicinal products, including innovative ones developed using biotechnology and artificial intelligence. In addition, the parties plan to focus on the development of competencies of GMP inspectorates.
The memorandum was signed by Vladislav Shestakov, Director of the FSI “SID & GP”, and Sami Al-Sager, Vice President of the Operational Sector of the SFDA of the Kingdom of Saudi Arabia.
“The memorandum marks a new stage in the development of cooperation in the field of GMP inspection between Russia and Saudi Arabia. Recognizing the importance of interaction and building trust between the regulatory systems of the two countries, we are joining forces to ensure that the population has access to effective, safe and high‑quality medicinal products. Through joint development of regulatory systems and good manufacturing practices, we will be able to build a transparent pharmaceutical circulation system,” noted Vladislav Shestakov, Director of FSI “SID & GP.”
